This P50 application is for the renewal of the Mayo SPORE In Brain Cancer for years 6-10. The SPORE will support a multidisciplinary team of basic and applied science investigators to perform translational research directed at significantly reducing morbidity and mortality from malignant gliomas. Brian Patrick O'Neill, M.D. will serve as Overall Principal Investigator and Director of the Administrative Core. Robert B. Jenkins, M.D., Ph.D. will serve as Overall Co-Principal Investigator and Administrative Core Co-Director. The translational research objectives of the SPORE will be directed by 14 investigators from 8 departments at Mayo Clinic in Rochester, all with a demonstrable history of collaborative and translational research. The SPORE comprises 4 Mayo investigator- initiated research projects and 4 scientific core resources consolidated by the Administrative Core. The SPORE also includes career development and developmental research programs. SPORE Research Projects 1. Influence of DNA repair on PARP inhibitor efficacy In GBM (Co-Leaders: J.N. Sarkaria, M.D., and N. Laack, M.D.) 2. Optimizing Measles Virotherapy In the Treatment of Gliomas (Co-Leaders: E. Galanis, M.D., D.Sc. and I.F. Parney, M.D., Ph.D.) 3. The Role of MMSET in DNA damage response and chemoradioresistance of glioblastoma (Co-Leaders: Z. Lou, Ph.D. and J. C. Buckner, M.D.) 4. Clinical Relevance of Chromosome 5p/9p/20q/8q Germline Alterations In Glioma (Co-Leaders: R. B. Jenkins, M.D., Ph.D and P. Yang, M.D., Ph.D. SPORE Scientific Cores A. Administrative Core (Director: B. P. O'Neill, M.D.;Co-Director: R.B. Jenkins, M.D., Ph.D.) B. Biostatistics Core (Director: K.V. Ballman, Ph.D.;Co-Director: W. Wu, Ph.D.) C. Pathology and Tissue Procurement Core (Director: C. Giannini, M.D., Ph.D.;Co-Director: F. Rodriguez, M.D.) D. Animal Core (Director: J.N. Sarkaria, M.D.;Co-Director: I.F. Parney, M.D., Ph.D.) E. Clinical Research Core (Director: J.C. Buckner, M.D.;Co-Director: D. H. Lachance, M.D.) Developmental Research Portfolio

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility, and adaptive skills. In addition to significant reduction in life expectancy each new malignant gliomas case impacts the nation's public health since its morbidity represents on average twenty years of lost productivity. Whether the payer is public or private, diagnosis and treatment, including supportive care in the terminal stages of disease, extracts enormous health care expenditures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-08
Application #
8535534
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Arnold, Julia T
Project Start
2004-09-20
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$2,084,586
Indirect Cost
$772,575
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol 19:493-502
Robinson, Steven; Galanis, Evanthia (2017) Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther 17:353-363
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2017) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol 131:41-48
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2017) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets :
Heim, Joel B; Squirewell, Edwin J; Neu, Ancilla et al. (2017) Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proc Natl Acad Sci U S A 114:3933-3938
Tivnan, Amanda; Heilinger, Tatjana; Ramsey, Joanne M et al. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:16605-16620
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016

Showing the most recent 10 out of 243 publications